UAB’s Director Of Infectious Diseases Warns Caution Around COVID-19 Vaccines In Trial
Dr. Jeanne Marrazzo speaks during a press conference September 3, 2020.
The director of infectious diseases at the University of Alabama at Birmingham says right now she would not take one of the COVID-19 vaccines currently in phase three clinical trials across the country.
During a press conference Thursday, Dr. Jeanne Marrazzo addressed the Centers for Disease Control’s announcement that a vaccine could be ready by the end of October. She said the vaccines have been fast-tracked and not much is known about their long term effects or success rates.
“Yes, I know there’s urgency, but we should not sacrifice our convenience for the rush to get a product that we just don’t know is really truly safe,” Marrazzo said. “We deserve the best. We deserve better. I mean people have been through hell with this thing.”
Efficacy trials, or better known as phase three trials, help determine if a vaccine works. In the case of COVID-19, for a phase three trial to be successful it must show that the vaccine reduces the number of actual infections in people and that participants are able to make antibodies against the virus over time.
But now, Marrazzo said, those efficacy standards may change with the release of data from a vaccine trial in the United Kingdom earlier this week.
“My big concern about this timeline that’s now out there is that not only do we not have the kind of evidence for efficacy, yet. Yet. I’m saying yet because maybe they know something I don’t know. That’s always possible,” Marrazzo said. “But do we really have confidence that we can go out there and vaccinate everybody safely without knowing the longer-term benefits or side effects of this vaccine?”
Marrazzo said she is also concerned that there is not enough information yet about long-lasting immunity to COVID-19, especially given recent reports of people being reinfected with the virus. She noted that the vaccines are based on a totally new technology.
“We have never had a messenger RNA vaccine in a human population before these trials,” Marrazzo said. “We think it’s safe, but we don’t know.”
She added that vaccines can have serious side effects. Marrazzo said phase three trials typically follow participants for at least a year, if not longer, to track possible side effects. If a vaccine is released in late October, it would have only been studied in humans for eight months – at most.
“We need iron-clad proof and assurance to the extent that anybody can get it in any vaccine study or any medical study that whatever product we make widely available to our citizens is as safe and effective as humanly possible,” Marrazzo said. “We are not there, right now. There’s no way I have seen, myself, and I know that most experts have seen enough data to feel like not only today there’s something to roll out but in seven short weeks … that there would be something to roll out.”
Marrazzo said ultimately the decision to get the vaccine is a risk-benefit analysis, but she will not get one unless it is backed by the Advisory Committee on Immunization Practices. Meanwhile, Marrazzo said she plans on volunteering for a vaccine clinical trial.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Smithsonian museums and National Zoo set to close as shutdown takes its toll
The shutdown is forcing the closure of a number of America's beloved cultural institutions starting Sunday. Twenty-one Smithsonian museums, its research centers and the National Zoo are all affected.
4 dead and 12 injured in a shooting after Mississippi homecoming game
The small town of Leland, Miss., was rocked by the shooting, which took place late Friday.
Africa’s oldest leader isn’t ready to retire – and he’s not the only one defying age
At 92, Cameroon's President aul Biya is running for an eighth term on Sunday — a reminder of how Africa's aging leaders continue to cling to power, even as their nations face unrest, corruption, and calls for change.
Photos celebrate the glory of girls on ‘International Day of the Girl’
October 11 is the "International Day of the Girl" on the United Nations calendar. These photos pay tribute to the spirit of girls in a world where they face many obstacles.
Luigi Mangione’s lawyers seek a dismissal of federal charges in CEO killing
Mangione's lawyers asked a federal judge to dismiss some criminal charges, including the only count for which he could face the death penalty, from a federal indictment brought against him.
Being your authentic self: NPR’s LGBTQ+ readers share their coming out stories
National Coming Out Day is Oct. 11. To celebrate and honor LGBTQ+ people who have come out and those who want to, NPR readers share how they told their loved ones.
